Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$470.18 14.84 (3.26%) as of 4:30 Mon 6/3


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 122.27(B)
Last Volume: 1,971,146 Avg Vol: 1,608,800
52 Week Range: $323.62 - $456.95
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 27,952 149,290 264,317 624,786
Total Sell Value $12,512,803 $62,732,519 $104,276,665 $212,070,018
Total People Sold 8 12 14 18
Total Sell Transactions 9 42 65 132
End Date 2024-03-03 2023-12-01 2023-06-02 2022-06-02

   
Records found: 3280
  Page 17 of 132  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Mcglynn Margaret G Director   –       •      –    2022-01-28 4 OE $127.54 $637,700 D/D 5,000 6,099     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2021-11-15 4 AS $186.80 $6,365 D/D (34) 33,589 38%     
   Arbuckle Stuart A EVP, COO   •       –      –    2021-11-15 4 AS $186.99 $562 D/D (3) 41,103 38%     
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-11-15 4 AS $186.78 $9,547 D/D (51) 31,928 38%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2021-11-01 4 D $185.07 $141,764 D/D (766) 32,576     -
   Kewalramani Reshma CEO & President   •       •      –    2021-08-19 4 B $195.14 $1,956,492 D/D 10,000 73,754 2.81 14%     
   Sachs Bruce I Director   –       •      –    2021-08-02 4 B $197.91 $2,968,650 D/D 15,000 41,210 2.39 5%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2021-07-30 4 D $200.39 $153,499 D/D (766) 33,342     -
   Bhatia Sangeeta N. Director   –       •      –    2021-06-02 4 AS $208.96 $117,216 D/D (559) 5,191 -15%     
   Mcglynn Margaret G Director   –       •      –    2021-06-01 4 D $0.00 $0 D/D (699) 1,099     -
   Bozic Carmen EVP and CMO   •       –      –    2021-05-28 4 D $210.04 $65,322 D/D (311) 32,953     -
   Liu Joy SVP, General Counsel   •       –      –    2021-05-17 4 AS $215.95 $24,230 D/D (112) 8,253 -15%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2021-05-17 4 AS $215.95 $24,230 D/D (112) 34,108 -15%     
   Arbuckle Stuart A EVP, Chief Comm & Ops Officer   •       –      –    2021-05-17 4 AS $215.33 $23,589 D/D (109) 41,103 -15%     
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-05-17 4 AS $215.59 $9,736 D/D (45) 40,133 -15%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2021-05-17 4 AS $215.31 $17,093 D/D (79) 33,589 -15%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2021-05-03 4 AS $218.06 $209,691 D/D (960) 34,108 -13%     
   Mckenzie Diana Director   –       •      –    2021-05-01 4 A $0.00 $0 D/D 1,842 3,277     -
   Carney Lloyd Director   –       •      –    2021-05-01 4 A $0.00 $0 D/D 1,842 5,401     -
   Mcglynn Margaret G Director   –       •      –    2021-05-01 4 A $0.00 $0 D/D 921 1,798     -
   Bhatia Sangeeta N. Director   –       •      –    2021-05-01 4 A $0.00 $0 D/D 1,842 5,750     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2021-05-01 3 IO $0.00 $0 D/D 0 1,394 -13%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2021-04-30 4 D $217.21 $166,383 D/D (766) 35,068     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2021-04-30 4 D $217.21 $118,814 D/D (547) 34,679     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-04-27 4 AS $215.58 $839,193 D/D (3,884) 40,133 -8%     
  3280 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 17 of 132
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us